Enzon Pharmaceut. - 500 Beiträge pro Seite

[FUNDAMENTAL7]

Enzon Pharmaceuticals' (ENZN - commentary - Cramer's Take) drug Oncaspar received expanded approval from the Food and Drug Administration to treat the rare blood cancer acute lymphoblastic leukemia.

The approval was based on safety data from trials involving 2,000 children with the disease. Oncaspar would be used in combination with other chemotherapy drugs in treating the condition.

The drug works by depleting leukemia cells of a certain amino acid necessary for their survival. Oncaspar was initially FDA-approved in 1994 to treat specific ALL patients who were overly sensitive to an enzyme known as L-asparaginase. The new labeling would allow Enzon to market the drug as a treatment for every patient with ALL, effectively doubling the market for the drug.

While ALL is expected to affect no more than 4,000 people in 2006, according to the American Cancer Society, it's the most common form of cancer in children, representing 23% of cancer diagnoses in patients younger than 15 years old. Without treatment, most patients don't survive more than five months.

Enzon's shares rose 28 cents, or 3.6%, to $7.98 Tuesday.

[ulife]

Langsam sollte mal wieder etwas Schwung in die Aktie kommen
Charttechnisch sieht das doch ganz pasabel aus
werd mir mal 500 st. reinlegen

[ulife]

hat keiner ein paar Infos, damit meine Zuversicht ein wenig besser wird??
Man hört und sieht kaumnoch was von Enzon

[FUNDAMENTAL7]

hallo ulife,

eine Nachricht über Enzon, damit du was zu lesen hast.

Enzon Pharmaceuticals Files Investigational New Drug Application for Novel HIF-1alpha Antagonist in Cancer

Fourth IND in 2006 Demonstrates Rapid Pipeline Progress


BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN - News) today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its HIF-1alpha (hypoxia-inducible factor 1alpha) antagonist, a highly-visible, well-validated target in many cancer types, including solid tumors.

2006 was a very exciting year for Enzon, as we began to build an innovative oncology pipeline, said Jeffrey Buchalter, Chairman and Chief Executive Officer of the Company. The filing of HIF-1alpha, our fourth IND submission in 2006, demonstrates our strong commitment to delivering on our promises and developing a differentiated cancer portfolio."

The target HIF- 1alpha functions as a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1alpha protein is too low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy. Drugs targeting HIF-1alpha thus have the potential to target multiple cancer processes.

Enzon licensed the HIF- 1alpha antagonist from Santaris in July 2006 along with the Survivin antagonist, and six additional proprietary RNA antagonist candidates, all directed against novel cancer targets selected by Enzon.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases. Enzon's specialized sales force markets Abelcet®, Oncaspar®, Adagen®, and Depocyt ® in the United States. In addition, Enzon also receives royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and MACUGEN®, marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a Customized Linker Technology(TM) PEGylation platform that utilizes customized linkers designed to release compounds at a controlled rate. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. The Company also engages in contract manufacturing opportunities with third parties to improve its efficiency. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our transition report on Form 10-K for the six-month period ended December 31, 2005 and our quarterly reports on Form 10-Q. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.



Mit Grüssen


Fundamental7

[FUNDAMENTAL7]

Ulife,

Hier noch eine Nachricht,uns zwar noch am gleichen Tag. damit so langsam deine Zuversicht kommt, falls du noch investiert bist.
Enzon ist einer der fundamental günstigsten Biotechaktien überhaupt. Es ist einer von sehr wenigen Biotechunternehmen die 5 Medikamente auf dem Markt haben, und noch hinzu einen Gewinn erzielen. Die Medikamente von Enzon sind leider keine Blockbuster geworden. Aber sie können jedoch die neuen Medikamente finanzieren,ohne aus der eigenen Kasse.
Enzon Seeks Start of Cancer Study
Thursday January 4, 5:36 pm ET
Enzon Pharmaceutical Asks FDA for Clearance to Begin Study on Possible Cancer Treatment

BRIDGEWATER, N.J. (AP) -- Enzon Pharmaceutical Inc. said late Thursday it asked the Food and Drug Administration to approve the start of clinical trials for its cancer treatment candidate.
The candidate, a HIF-1 alpha antagonist, is a highly validated target in several cancer types, including solid tumors, the company said. Drug targeting could possibly treat multiple cancer processes.

Enzon licensed the compound from Santoris in July along with several others targeting cancer.

Shares of Enzon rose 22 cents, or 2.7 percent, to close at $8.41 on the Nasdaq. The stock gained an additional 59 cents, or 7 percent, to reach $9 in after-hours electronic trading.



Mit Grüssen

Fundamental7

[ulife]

Danke für die Infos
Hab Enzon schon lange, damals galt sie bei "Aktionär" als konservative Depotbeimischung (dann ist sie von 70 Euro gen süden)
Naja
Darüber brauch ich nichts weiter zu sagen
Am Besten man geht schnellstens raus aus den Empfehlungen vom "Aktionär"
Inzwischen hab ich bischen nachgekauft und liegen gelassen
Ist doch immer am Erfolgreichsten, Aktien nicht nur 14 tage zu halten, sondern eher 14 Jahre

[FUNDAMENTAL7]

Man sollte natürlich langfristig in eine Aktie investieren, nur so ist es gewährleitet dass die Geduld mitspielt, und man nicht bei jeder Bewegung nach unten verkäuft.
Natürlich sollte man versuchen eine Aktie so günstig wie möglich erwischen. Der erste Versuch scheitert immer, denn man kann fast nie eine Aktie zum tiesten Punkt erwischen. Aber man kann durch Nachkäufe sichern dass man zumindest den "Durchschittseinstiegskurs" mindert.

Aber damals für Enzon 70 Dollar auszugeben, ist eigentlich wahnsinn. Wenn man bedenkt dass sie dann etwa über 3 Milliarden bewertwet war.Diesen Fehler haben wir alle gemacht, dass wir die Zeitschriften wie Aktionär, Euro am Sonntag u.s.w. vertraut haben.
Wie kann mann dieses Unternehmen bei 70 Dollar empflehlen ???? Wer dies tur hat selbst keine Ahnung oder profitiert davon uns zu belügen. Ich tippe eigentlich das erste , dass sie keine Ahnung haben was sie schreiben. Sie wissen nicht was sie sagen, aber verdienen mit dem Zeitschriften sich dumm und dähmlich.
Wenn wir es zulassen, und dumm um dähmlich die Zeitschriften weiter abonieren sind wir eigentlich die Dähmlichen.

[ulife]

da hast du recht
inzwischen sieht die sache besser für mich aus,
Beharlichkeit zahlt sich aus
viele meiner Bekannten sind ganz ausgestiegen und raufen sich inzwischen die Haare
Meine Verluste von 2000 sind wenigstens wieder reingeholt
Wenn Enzon wieder auf 20 geht mach ich eh ´nen Fass auf.

[ulife]

29.03.2007 14:10
Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha Antagonist
Enzon Pharmaceuticals, (Nachrichten) Inc. (Nasdaq: ENZN) today announced that the first patient has been enrolled in its clinical study of the HIF-1 alpha antagonist (EZN-2968). The open-label, non-randomized study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha antagonist in 30 to 40 patients with advanced solid tumors or lymphoma.

Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1 alpha is low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy. Drugs targeting HIF-1 alpha thus have the potential to target multiple cancer processes.

“We are very pleased with the rapid advancement we have made on this important project,“ said Jeffrey Buchalter, chairman and chief executive officer. “We are very focused on developing innovative therapeutics to treat cancer, and this well validated target is a very exciting addition to our clinical portfolio.“

Enzon licensed the HIF-1 alpha antagonist from Santaris in July 2006 along with the Survivin antagonist and six additional proprietary product candidates created using the Locked Nucleic Acid technology platform, all directed against novel cancer targets selected by Enzon.

For more information on this study, or to find a participating center and eligibility criteria, please visit

Quelle: Buisness Wire

[FUNDAMENTAL7]

FDA Grants Full Approval for DepoCyt(R) for the Treatment of Lymphomatous MeningitisFriday April 20, 8:00 am ET


BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN - News) today announced that the US Food and Drug Administration (FDA) has granted full approval for DepoCyt® (cytarabine liposome injection) for the treatment of patients with lymphomatous meningitis, a life-threatening complication of lymphoma. DepoCyt was originally approved under the Accelerated Approval regulations of Subpart H of the Food, Drug and Cosmetic Act, based on a preliminary demonstration of an increased complete response rate compared to unencapsulated cytarabine.

The full approval was based on findings from two randomized controlled clinical trials that included over 200 patients with neoplastic meningitis related to solid tumors, lymphoma or leukemia. The first study demonstrated that more patients with lymphomatous meningitis treated with DepoCyt showed an absence of neurological progression of the disease. The second study showed an increase in complete cytologic responses among patients treated with DepoCyt, as defined by a clearing of malignant cells in the cerebrospinal fluid (CSF).

"The FDA's full approval of DepoCyt is an important milestone for this unique product that has benefited those suffering from this devastating complication of cancer since its introduction to the market in 1999," said Jeffrey H. Buchalter, Chairman and Chief Executive Officer of Enzon. "Furthermore, we are pleased all of the FDA requirements have been met and we can continue to make this product available to the patients who need it."

DepoCyt is manufactured by SkyePharma Inc.

About DepoCyt

DepoCyt is a sustained release formulation of the chemotherapeutic agent, cytarabine, used for the treatment of patients with lymphomatous meningitis. Lymphomatous meningitis can be controlled with cytarabine, but because of the drug's short half-life, a spinal injection is required twice per week, whereas DepoCyt is dosed once every two weeks. DepoCyt gradually releases cytarabine into the cerebral spinal fluid resulting in a significantly extended half-life, prolonged exposure to the therapy, and a more uniform distribution.

Important safety information

DepoCyt® (cytarabine liposome injection) should be administered only under the supervision of a qualified physician experienced in the use of intrathecal cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available. In all clinical studies, chemical arachnoiditis, a syndrome manifested primarily by nausea, vomiting, headache and fever, was a common adverse event. If left untreated, chemical arachnoiditis may be fatal. The incidence and severity of chemical arachnoiditis can be reduced by coadministration of dexamethasone. Patients receiving DepoCyt should be treated concurrently with dexamethasone to mitigate the symptoms of chemical arachnoiditis.

About Lymphomatous Meningitis

Lymphomatous meningitis is a complication of lymphoma that is characterized by the spread of the cancer to the central nervous system and the formation of secondary tumors within the thin membranes surrounding the brain. Symptoms can include numbness or weakness in the extremities, pain, sensory loss, double-vision or loss of vision, hearings problems, and headaches.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

About SkyePharma Inc.

SkyePharma Inc. is a wholly owned subsidiary of Blue Acquisition Corp., a Delaware corporation, which is controlled and funded by a group of financial investors including MPM Capital, OrbiMed Advisors, HBM Bioventures (Cayman) LTD. and Sanderling Ventures,. This business is based in San Diego, CA, and formulates, develops and manufactures controlled-release injectable products based on two proprietary drug delivery platforms: DepoFoam and Biospheres. Revenues are generated from two marketed products: DepoCyt for lymphomatous meningitis and DepoDur for the treatment of post-surgical pain.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the 12-month period ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.



Contact:
Enzon Pharmaceuticals, Inc.
Craig Tooman
EVP, Finance and Chief Financial Officer
908-541-8777

[Utzelchen]

Heidewitzka, selbst die Anleger sind nicht gut auf Enzon zu sprechen, was ich bei diesem Werdegang auch absolut verstehen kann.



http://www.worldofinvestment.com/wkn/873997/

Seid ihr eigentlich immer noch investiert oder verkauft? ist so ruhig hier im Thread!

[FUNDAMENTAL7]

Antwort auf Beitrag Nr.: 30.878.263 von Utzelchen am 27.07.07 16:01:17

Wir warten einfach, Tee trinken und warten was anderes bleibt uns nicht übrig Irgendwann werden wir höhere Kurse sehen können. Wann genau ?? Ich weiss es halt nicht.






Mit Grüssen Fundamental7